iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Plasma Interferon-γ-Inducible Protein 10 (IP-10) and Response to
Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype
1-Infected Patients With and Without Cirrhosis - Abbvie Analysis
 
 
  " In the era of interferon (IFN)-based therapies for hepatitis C virus (HCV) infection, elevated interferon-γ-inducible protein 10 (IP-10; CXCL10) levels predicted poor virologic response, particularly when associated with an unfavorable IL28B non-CC genotype1,2......[this study found] SVR rates were similar irrespective of elevated baseline IP-10 levels with prospective confounding factors of IL28B genotype, HCV sub genotype, and race (Figure 3)"
 
Reported by Jules Levin
DDW 2015
Digestive Disease Week, May 17-19, 2015, Washington, DC
 
Jordan J Feld1, Gregory J Dore2, David Wyles3, Eric Lawitz4, Andrew H Talal5,6, Greg Ball7, Emily O Dumas7, Ira M Jacobson5 1Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 2Kirby Insti tute, UNSW Australia, and St. Vincent's Hospital, Sydney, Australia; 3University of California San Diego, La Jolla, California, United States; 4The Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 5Weill Cornell Medical College, New York, New York, United States; 6University at Buffalo, Buffalo, New York, United States; 7AbbVie Inc., North Chicago, Illinois, United States; 8Icahn School of Medicine at Mount Sinai, New York, New York, United States

HCV1.gif

HCV2.gif

HCV3.gif

HCV4.gif

HCV5.gif

HCV6.gif

HCV7.gif

HCV8.gif

HCV9.gif

HCV10.gif

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org